Showing results (191-200 of 249) with videos related to
Sort By:
Pageof 25
Preparative Biochemistry|January 1, 1975
Structural and compositional changes attending the ultracentrifugation of very low density lipoproteinsP N Herbert, T M Forte, R S Shulman, et al.Archives of Dermatology|September 1, 1994
Clinical improvement following dermabrasion of photoaged skin correlates with synthesis of collagen IB R Nelson, G Majmudar, C E Griffiths, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman, Michael D Hughes, Mark A Winters, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1983
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cellsA M Dvorak, H F Dvorak, S P Peters, et al.Antiviral Therapy|February 6, 2004
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistanceJoel E Gallant, Peter Z Gerondelis, Mark A Wainberg, et al.European Journal of Gastroenterology & Hepatology|May 16, 2018
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)Vasily Isakov, Dzmitry Paduta, Rolando M Viani, et al.The Journal of Infectious Diseases|March 23, 2017
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid Wyles, Michael Saag, Rolando M Viani, et al.Pediatric Blood & Cancer|September 16, 2023
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcomaKevin Campbell, Andrew Posner, Nan Chen, et al.Antimicrobial Agents and Chemotherapy|August 8, 2012
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevirS Le Pogam, J M Yan, M Chhabra, et al.Journal of Hepatology|March 1, 2011
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patientsEdward J Gane, Regine Rouzier, Catherine Stedman, et al.Pageof 25